Rly2608
WebMar 22, 2024 · Pan-mutant and isoform selective PI3Kα inhibitor， RLY-2608， demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients， ReDiscover trial. 泛PI3Kα抑制剂RLY-2608在PIK3CA突变体实体瘤患者中的首次人体研究：ReDiscover ... WebSep 13, 2024 · The Dynamo™ platform enabled the discovery of RLY-2608, the first allosteric, pan-mutant (H1047X, E542X and E545X), and isoform-selective PI3Kα inhibitor designed to overcome these limitations. RLY-2608 is on path to initiate a first-in-human clinical trial in the first half of 2024. About Relay Therapeutics
Rly2608
Did you know?
WebTrial ID RLY-2608-101. Sponsor ID Relay Therapeutics. A First-in-Human Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer. Principal Investigator. Alexander I. Spira, MD, PhD, FACP. 1 Location. Breast. Solid Tumors All. WebRLY-2608 overview. RLY-2608 is under development for the treatment of solid tumors, metastatic breast cancer, HR positive/human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer). It is administered through oral route. It is a small molecule and acts by targeting H1047X, E542X and E545X mutant phosphoinositide 3 ...
WebApr 11, 2024 · Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial When : Apr. 18, 2024 ... WebJan 31, 2024 · This is an open-label, FIH study designed to evaluate the maximum tolerated dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of …
WebApr 13, 2024 · Their lead candidate, RLY-2608, has shown promise in preclinical studies. The upcoming release of Phase 1 data for RLY-2608 on 18th April could be a game-changer for Relay. Positive results would validate their AI-driven Dynamo platform and p otentially drive up the stock price significantly. WebMar 6, 2024 · About RLY-2608. RLY-2608 is the lead program of multiple efforts to discover and develop mutant selective inhibitors of PI3Kα. PI3Kα is the most frequently mutated kinase in all cancers, with ...
WebDrug Name: RLY-2608: Trade Name: Synonyms: RLY 2608 RLY2608: Drug Descriptions: RLY-2608 selectively inhibits PIK3CA. with higher selectivity and potency against mutant forms of PIK3CA (including PIK3CA E542K, PIK3CA E545K, and PIK3CA H1047R), leading to decreased downstream signaling, and potentially resulting in reduced tumor cell viability …
WebJulia E. McGuinness, MD, discusses the rationale for combining this novel PI3K inhibitor with fulvestrant and emphasized the importance of developing increasingly mutant-specific PI3K inhibitors… heating pad for stomach acheWebFeb 15, 2024 · RLY-2608 can be combined with fulvestrant and CDK4/6 inhibitors in vivo with tumor regressions observed in both cell- and patient-derived xenograft models. The pre … movie theaters in meadvilleWebJan 31, 2024 · First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. movie theaters in melrose park ilWebJan 4, 2024 · Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor. Selects 70 mg once-daily dose for RLY-4008 and … movie theaters in melbourne flWebMar 13, 2024 · Currently two investigational agents of this class have entered early phase 1 clinical trials: RLY-2608 and LOXO-783 and several in pre-clinical development, e.g. STX-478. RLY-2608. heating pad for stoveWebDec 20, 2024 · The study will evaluate both RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors and RLY-2608 + fulvestrant combination arm for … movie theaters in menifee californiaWebMar 14, 2024 · In 2024, Relay Therapeutics (NASDAQ:RLAY) continued evaluating RLY-2608 in combination with fulvestrant for patients with HR+, HER2–, PI3Kα-mutated, locally advanced or metastatic breast cancer. heating pad for snake cage